Note 13 - Share Capital (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||
| Notes To Financial Statements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Earnings Per Share, Basic and Diluted |
Loss per Common Share is calculated using the weighted average number of Common Shares outstanding and is presented in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Total Anti-dilutive Shares |
The effect of any potential exercise of the Company’s stock options and warrants outstanding during the years ended December 31, 2025 and December 31, 2024 has been excluded from the calculation of diluted loss per common share as it would be anti‑dilutive.
|
|||||||||||||||||||||||||||||||||||||||||||||